Allosteric Plus Catalytic BCR-ABL1 Inhibitors Promote Durable Responses.
Sign Up to like & getrecommendations! Published in 2017 at "Cancer discovery"
DOI: 10.1158/2159-8290.cd-rw2017-062
Abstract: A selective allosteric ABL1 kinase inhibitor suppresses the growth of BCR-ABL1-driven CML. read more here.
Keywords: catalytic bcr; abl1; plus catalytic; allosteric plus ... See more keywords